GlassScriptPhysician profile
Maryam Nisa
NPI 1992284095
$7,284.02
in general payments reported to CMS, 2019-2025
33 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $512 · 2022: $950 · 2023: $1,519 · 2024: $2,409 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,821.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,364.19 | 2021-2025 | |
| Janssen Biotech, INC. | $890.25 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $666.02 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $541.35 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $525.17 | 2021-2025 | Entyvio, Gattex |
| Genzyme Corporation | $366.62 | 2022-2025 | |
| Ardelyx, INC. | $279.61 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $272.87 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $238.84 | 2023-2025 | Ocaliva |
| Qol Medical, LLC | $238.23 | 2022-2024 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $213.69 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $206.82 | 2023-2025 | Vowst |
| Ironwood Pharmaceuticals, INC | $156.02 | 2022-2024 | Linzess |
| Gilead Sciences, INC. | $147.53 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $125.09 | 2021-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $108.14 | 2024-2025 | Iqirvo |
| Celgene Corporation | $103.17 | 2023-2024 | Zeposia |
| Daiichi Sankyo INC. | $102.39 | 2024 | Injectafer |
| Lilly USA, LLC | $100.18 | 2024-2025 | Omvoh |
| Organon LLC | $86.52 | 2023-2024 | Hadlima, Renflexis |
| Celltrion USA INC. | $80.55 | 2024-2025 | Vegzelma |
| Amgen INC. | $80.30 | 2022-2023 | Avsola, Amjevita |
| Phathom Pharmaceuticals, INC. | $75.88 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $55.62 | 2024 | Tremfya |
| Sandoz INC. | $51.48 | 2023 | Hyrimoz |
| Digestive Care, INC. | $39.29 | 2021-2025 | Pertzye |
| Braintree Laboratories, INC. | $34.07 | 2021-2023 | Suflave |
| Redhill Biopharma INC. | $32.65 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.36 | 2022-2023 | Zinplava, Dificid |
| Exact Sciences Corporation | $21.86 | 2023 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $17.61 | 2022 | |
| Evoke Pharma, INC. | $16.78 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $15.87 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryam Nisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.